Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Oxford BioDynamics ( (GB:OBD) ) has provided an update.
Oxford BioDynamics has announced promising results from a clinical study on its EpiSwitch® CRC Blood Test, which detects colorectal cancer and precancerous polyps with high accuracy. The study, published in a peer-reviewed journal, demonstrates the test’s 81% accuracy for early cancer detection and 82% for non-cancerous polyps. This advancement marks a significant step in non-invasive cancer screening, potentially transforming clinical practice and enhancing stakeholder value. Discussions with potential partners to bring this test to market are underway, highlighting its potential impact on the industry and positioning Oxford BioDynamics as a leader in precision diagnostics.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company focusing on personalized healthcare by developing precision clinical diagnostic tests for various life-changing diseases. It has two commercially available products: the EpiSwitch® PSE, which enhances the predictive accuracy of prostate cancer testing, and the EpiSwitch® CiRT, a predictive response test for immuno-oncology treatments. The company’s proprietary 3D genomic biomarker platform, EpiSwitch®, aids in diagnosing and predicting treatment responses. Oxford BioDynamics is headquartered in Oxford, UK, with operations in Maryland, USA, and Penang, Malaysia, and is listed on the London Stock Exchange’s AIM.
YTD Price Performance: -66.67%
Average Trading Volume: 3,491,952
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.76M
See more insights into OBD stock on TipRanks’ Stock Analysis page.
